Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Oric Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
19
22.8
35.9
56.9
61.7
85.2
114
110
General and administrative
3.35
5.73
13.4
22
25.1
25.6
28.8
33.2
Operating expenses
22.4
28.6
74.2
78.9
91.8
111
143
143
Operating income
-22.4
-28.6
-74.2
-78.9
-91.8
-111
-143
-143
Other non-operating income
1.01
1.69
0.48
0.16
2.65
10.1
15
13.5
Income tax
0
0
0
0
0
0
0
0
Net income
-21.4
-26.9
-73.7
-78.7
-89.1
-101
-128
-129
EBITDA
-21.5
-27.5
-73.2
-78
-90.8
-110
-142
-142
EPS, basic
-12.32
-14.15
-3.36
-2.07
-2.25
-1.96
-1.83
-1.47
EPS, diluted
-12.32
-14.15
-3.36
-2.07
-2.25
-1.96
-1.83
-1.47
Shares, basic (weighted)
1.73
1.9
21.9
38
39.7
51.5
69.7
87.8
Shares, diluted (weighted)
1.73
1.9
21.9
38
39.7
51.5
69.7
87.8
Balance sheet
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
42.6
89.2
78.4
226
66.8
23.4
59.4
45.7
Short-term investments
215
11
139
185
197
236
Other current assets
0.84
3.1
3.54
4.19
4.41
6.29
6.98
Total current assets
90
297
241
210
213
262
288
Property, plant and equipment
2.24
1.98
2.41
3.25
2.86
2.92
2.42
Lease right-of-use assets
11.8
11
9.14
8.38
6.66
Long-term investments
0
43.4
22
26.9
0
111
Other non-current assets
1.85
0.32
12.3
11.5
9.7
8.97
7.25
Total assets
94.1
299
299
247
252
274
409
Accounts payable
0.15
0.76
1.89
1.32
0.94
1.55
3.82
Accrued liabilities
5.2
8.25
13.3
14.1
19.5
23.3
16.6
Total current liabilities
5.35
9
15.2
15.4
20.5
24.8
20.4
Lease liabilities
10.5
9.44
7.46
6.17
4.11
Other non-current liabilities
0.22
10.5
9.44
7.46
6.17
4.11
Total liabilities
6.12
9.22
25.7
24.8
27.9
31
24.5
Total debt
10.5
Paid-in capital
2.61
456
518
558
659
806
1,076
Retained earnings
-92.7
-166
-245
-334
-435
-563
-692
Other comprehensive income
-0.03
-0.1
-1.29
0.26
0.38
0.79
Shareholders' equity
-64.4
-90.1
290
273
222
224
243
384
Total equity
-64.4
-90.1
290
273
222
224
243
384
Total liabilities and equity
94.1
299
299
247
252
274
409
Shares outstanding
1.98
36.7
39.4
45.1
54.9
71
98.5
Cash flow statement
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-21.4
-26.9
-73.7
-78.7
-89.1
-101
-128
-129
Depreciation and amortization
0.9
1.03
0.97
0.9
0.97
1.03
1.11
1.22
Stock-based compensation
0.47
1.09
5.28
12.9
14.5
15.2
20.2
25
Change in payables
-0.41
0.99
4.3
2.93
-1.48
3.28
1.83
-7.25
Cash from operations
-20.7
-23.5
-45.3
-59.5
-75.1
-85.7
-113
-111
Capital expenditures
-0.53
-0.77
-0.67
-0.94
-2.08
-0.85
-1.19
-0.71
Purchases of investments
-225
-69.6
-238
-239
-252
-400
Sales and maturities of investments
10
229
131
197
275
253
Cash from investing
-0.51
-0.77
-216
158
-109
-43.4
22.1
-148
Stock issued
0.08
0.13
271
50
25
85
125
244
Cash from financing
38
70.8
251
49.1
25.2
85.7
127
245
Net change in cash
16.8
46.5
-10.7
148
-159
-43.4
36
-13.7
Free cash flow
-21.2
-24.3
-45.9
-60.5
-77.2
-86.5
-114
-112
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $13.16 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-36.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-34.7%
Net income / average total assets.
Return on invested capital (ROIC)
-35.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
58.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
20.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
5.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
49.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
18.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
6.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
25.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
30.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
32.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
13.2x
Current assets / current liabilities.
Quick ratio
12.8x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
12.8x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.04
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.03
Cash from operations / diluted weighted shares.
Book value per share
$3.68
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
3.58x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.58x
Market cap / tangible book value, when positive.
FCF yield
-8.2%
Free cash flow / market cap.
Earnings yield
-10.3%
Net income / market cap (the inverse of P/E).
Was Oric Pharmaceuticals, Inc. profitable in fiscal 2025?
No. It reported a net loss of $129.5M.
How much free cash flow did Oric Pharmaceuticals, Inc. generate in fiscal 2025?
Cash from operations of $111.0M minus capital expenditures of $712.0K left free cash flow of -$111.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.